InterMed Discovery GMBH
This article was originally published in Start Up
InterMed Discovery has its own natural products discovery platform, IMD Bioprofiling, and two thriving product pipelines in food and pharmaceuticals. IMD Bioprofiling incorporates a large natural product library of biologically active substances and extracts, a discovery engine deriving products from these sources, and NPsilico, a database of literature and proprietary biological data on bioactive natural products. InterMed will support partners in research and lead generation, and also generate a proprietary product pipelines in pharmaceuticals, functional food ingredients, and functional cosmetics ingredients.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Nanotechnology, a Balm for the Challenges of Drug Delivery," features profiles of BIND Biosciences, Liquidia Technologies, Nanolymf, Tempo Pharmaceuticals, and TransGenex Nanobiotech. Plus these Start-Ups Across Health Care: Breathe Technologies, Crospon, and InterMed Discovery.
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways